We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Palynziq

News List

EU approval for Palynziq in adult phenylketonuria pharmatimes
May 09, 2019
The European Commission has approved BioMarin’s Palynziq (pegvaliase injection) for the treatment of phenylketonuria (PKU) in patients aged 16 years or older.
EU approval for Palynziq in adult phenylketonuria pharmatimes
May 09, 2019
The European Commission has approved BioMarin’s Palynziq (pegvaliase injection) for the treatment of phenylketonuria (PKU) in patients aged 16 years or older.
FDA Approves Palynziq drugs
May 31, 2018
The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU).
FDA approves Palynziq for PKU, a rare and serious genetic disease europeanpharmaceuticalreview
May 29, 2018
Novel enzyme therapy for adults with PKU who have uncontrolled blood phenylalanine concentrations with current treatment…